Collegium Pharmaceutical Receives $22,500,000 New Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f419bf02-c8ca-4a43-a3a8-f5bf2ee5cf21&Preview=1
Date
2/22/2012
Company Name
Collegium Pharmaceutical
Mailing Address
400 Highland Corporate Drive Cumberland, RI 02864
Company Description
Collegium Pharmaceutical is dedicated to the development of proprietary, late stage pharmaceutical products that add market value and clinical benefit to existing drugs. We apply customized pharmaceutical formulations and intellectual property (IP) strategies to drugs that are safe and effective, creating a portfolio of improved pharmaceutical products with a shorter time to market.
Website
http://www.collegiumpharma.com
Transaction Type
Venture Equity
Transaction Amount
$22,500,000
Transaction Round
Undisclosed
Proceeds Purposes
The round will fund the company for three years. In that time, it expects to file for U.S. approval of a version of oxycodone designed to be harder to tamper with than existing forms of this opioid narcotic.
M&A Terms
Venture Investor
Longitude Capital Management
Venture Investor
Skyline Ventures
Venture Investor
Boston Millennia Partners
Venture Investor
Frazier Healthcare Ventures